Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii which can have serious consequences for the fetus in case of pergravidicseroconversion. The present work is analytical and descriptive complementary studies: prospective (1-09-2015 to 31-12-2015) and a retrospective study (01-01-2010 to 31-12-2014) performed in the service of Parasitology - Mycology Marrakesh.The seroprevalence of pregnant women immunized against toxoplasmosis in our study is 35%, including women from rural and illiterate are proven to be the most immune. The main risk factors for disease transmission are the lack of knowledge about toxoplasmosis, the modes of transmission and means of prevention, and the low level of hygiene. We also raised a blatant lack of regular serological monitoring in seronegative pregnant women who received only one serological test in 66%. The present study confirmed that more than half of pregnant women are not immunized against Toxoplasma gondii and deserve monthly monitoring for early detection of possible seroconversion and implement effective therapeutic management.

Background Medical cannabis has been legal in Canada since 2001, and recreational cannabis was legalized in October 2018, which has led to a widespread increase in the accessibility of cannabis products. Aims This study aimed to estimate the prevalence of cannabis use among adults living with chronic pain (CP) and investigate the relationship between age and cannabis use for CP management. Methods A cross-sectional analysis of the COPE Cohort data set, a large Quebec sample of 1935 adults living with CP, was conducted. Participants completed a web-based questionnaire in 2019 that contained three yes/no questions about past-year use of cannabis (i.e., for pain management, management of other health-related conditions, recreational purposes). Results Among the 1344 participants who completed the cannabis use section of the questionnaire, the overall prevalence of cannabis use for pain management was 30.1% (95% confidence interval 27.7–32.7). Differences were found between age groups, with the highest prevalence among participants aged ≤26 years (36.5%) and lowest for those aged ≥74 years (8.8%). A multivariable logistic model revealed that age, region of residence, generalized pain, use of medications or nonpharmacological approaches for pain management, alcohol/drug consumption, and smoking were associated with the likelihood of using cannabis for pain management. Conclusions Cannabis is a common treatment for the management of CP, especially in younger generations. The high prevalence of use emphasizes the importance of better knowledge translation for people living with CP, rapidly generating evidence regarding the safety and efficacy of cannabis, and clinicians’ involvement in supporting people who use cannabis for pain management.

No abstract